The 200 patient, multi-center, European trial is designed to investigate the safety and efficacy of udenafil, a long acting phosphodiesterase type 5 inhibitor.
Dong Hyun Park, president and CEO of Dong-A PharmTech, said: “Dong-A PharmTech is continuing its development of udenafil for erectile dysfunction in the USA and will develop udenafil for other indications such as benign prostatic hyperplasia and pulmonary hypertension.”